Avacta Group (LON:AVCT) Hits New 52-Week High – Should You Buy?

Avacta Group Plc (LON:AVCT) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 83.20 and last traded at GBX 80, with a volume of 2869779 shares trading hands. The stock had previously closed at GBX 81.

Analyst Upgrades and Downgrades

Separately, Peel Hunt reiterated a “buy” rating and issued a GBX 99 price target on shares of Avacta Group in a research note on Monday, October 13th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of GBX 99.

Avacta Group Stock Down 1.2%

The company has a current ratio of 1.29, a quick ratio of 4.96 and a debt-to-equity ratio of 52.53. The business has a 50 day moving average of GBX 64.85 and a 200-day moving average of GBX 48.23. The stock has a market cap of £326.61 million, a PE ratio of -4.56 and a beta of 1.12.

Avacta Group (LON:AVCT) last announced its earnings results on Tuesday, September 30th. The biotechnology company reported GBX (4.46) earnings per share (EPS) for the quarter. Avacta Group had a negative return on equity of 74.00% and a negative net margin of 114.45%. Equities research analysts predict that Avacta Group Plc will post -9.9011833 EPS for the current fiscal year.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).